Last updated on November 2019

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients With Advanced Systemic Mastocytosis

Brief description of study

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

Clinical Study Identifier: NCT03580655

Find a site near you

Start Over

Stanford Cancer Institute

Stanford, CA United States
  Connect »

Mays Cancer Center

San Antonio, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »